ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

November 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

November 11, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

November 07, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

November 05, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

September 03, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

August 12, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

June 16, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 19, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

May 14, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

March 24, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

March 06, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

January 28, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

January 08, 2025

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

November 12, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

November 04, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

September 26, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

September 12, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

September 11, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

September 10, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

August 27, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 21, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

August 13, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

June 10, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

May 21, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

May 13, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

April 23, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

April 23, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

April 22, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

March 28, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

February 22, 2024

From Centessa Pharmaceuticals plc

Via GlobeNewswire

Tickers CNTA

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.